Browse Category

Company Analysis News 8 October 2025 - 14 October 2025

HCL Tech’s AI-Powered Pivot Ignites Stock Rally – Brokers Say It’s Better Than TCS

HCL Tech’s AI-Powered Pivot Ignites Stock Rally – Brokers Say It’s Better Than TCS

Robust Q2 Results and AI Gains HCLTech’s Q2FY26 report (for Sept 30) stunned analysts with broad-based strength. Consolidated revenue grew 10.7% YoY to ₹31,942 crore and sequential profit rose ~10.2% economictimes.indiatimes.com, topping surveys. Notably, the company disclosed ₹886 crore ($100M)
Safe & Green (NASDAQ:SGBX) Sparks Speculation: Nasdaq Comeback & Bold Moves Ignite Interest

Safe & Green (NASDAQ:SGBX) Sparks Speculation: Nasdaq Comeback & Bold Moves Ignite Interest

Safe & Green Holdings announced multiple strategic moves recently, including regaining Nasdaq compliance (Oct. 3, 2025) and executive pay converted to stock ir.safeandgreenholdings.com ir.safeandgreenholdings.com. Company Profile & Business Model Safe & Green Holdings (NASDAQ: SGBX) is a diversified modular solutions
Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Adaptimmune Therapeutics (ADAP) Stock Skyrockets 42% – Is This Biotech Turnaround for Real?

Therapy (Target) Indication Status (2025) Current Ownership TECELRA(afamitresgene, targets MAGE-A4) Synovial sarcoma (unresectable/metastatic) FDA approved Aug 2024 biospace.com; ~16 patients treated in launch year nasdaq.com. Sold to US WorldMeds (2025) adaptimmune.com Letetresgene (lete-cel, NY-ESO-1) MRCLS and synovial sarcoma (advanced solid tumors) Phase
8 October 2025
Go toTop